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Abstract
Background: There are many studies about the prognosis and possible predictive factors of mortality for pediatric
allogeneic hematopoietic stem cell transplantation (HSCT) recipients requiring pediatric intensive care unit (PICU)
treatment, but the related study in China is lacking. This study investigates the data of these special patients in our
center.
Methods: This retrospective analysis is based on data from bone marrow center and PICU of our hospital. A total of
302 patients received allogeneic HSCT from January 2000 to December 2012, 29 of them were admitted to PICU
because of various complications developed after transplantation. We collected the clinical data, identified the
reasons why the patients to PICU, analyzed the mortality of these patients in PICU, and the prognostic factors of
these patients.
Results: The main reasons for admission were: respiratory failure (62.07 %), neurological abnormities (13.79 %), renal
failure (13.79 %) and others (10.35 %). Twenty-one cases (72.41 %) died. Compared with survivors, the deaths cases
had lower pediatric critical illness score (77 vs. 88, p = 0.004); higher levels of lactic acid and serum urea nitrogen (4.
02 vs. 1.19 mmol/L, P = 0.008;11.56 vs. 7.13 m moll /L, P = 0.045); more organs damaged (2.05 vs. 1.38, P = 0.01), and
required more supportive treatments (1.52 vs. 0.63, P = 0.02). Univariate analysis identified pediatric critical illness
score, use of mechanical ventilation, and the number of supportive treatment as the significant predictors to
prognosis. Multivariate analysis by regression showed that pediatric critical illness score was the only independent
prognostic factor (P = 0.035).
Conclusions: In our study, pediatric allogeneic HSCT recipients who had PICU care had a high rate of mortality.
Pediatric critical illness score was the independent prognostic factor for these patients.
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Background
Since the first patient received bone marrow transplant-
ation in 1950, HSCT has progressed to be widely used in
a range of malignant or nonmalignant diseases [1]. In
2008, approximately 2,400 children received HSCT in
North America. Of those, approximately 90 % of the
indication for transplant was malignancy [2, 3]. With the
increase of patients who have received HSCT, there has
been an increasing necessity for adequate ICU service to
manage various transplant related complications. It is
reported that about 3.3–35 % of patients receiving
HSCT will require ICU admission, and of those requir-
ing ICU admission the mortality ranged from 37–74 %
[4–12]. Although there have been many studies abroad,
there is limited data from China. Our study aims to
investigate the prognosis of HSCT patients in our center,
and to elucidate any possible predictors of mortality.
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This is a retrospective case–control study. Tertiary PICU.
The study cohort consisted of patients less than 18 years
old who were admitted to PICU from January 2000 to
December 2012 because of various complications devel-
oped after allogeneic HSCT. The doctors of BMT and
PICU co-managed the patients. All patients' legal guard-
ians signed an informed consent form. The Institutional
Review Board at the Shanghai Children’ Medical Center
approved the study protocol.
From a chart review, general demographic data, under-
lying diseases, duration of pre-transplant, transplant type,
donor source, and preprocessing scheme (myeloablative,
non-myeloablative) were collected. Additionally, all prior
post-transplant history was reviewed. Within the first day
of admission to PICU, the time from transplant was deter-
mined, the pediatric critical illness score (PCIS) was calcu-
lated, laboratory tests were completed (complete blood
count, hepatic, renal, coagulation studies, and arterial
blood gas), and the type of supportive treatment required
was documented (mechanical ventilation, vasoactive agents
therapy, renal replacement therapy). The duration of
mechanical ventilation, length of PICU stay, and outcome
of PICU was collected. Additionally, 30-day and 6-month
follow up occurred to determine survival at these time
intervals.
Statistical analysis
Continuous variables were compared using the
Mann—Whitney U-test. Categorical characteristics were
assessed by the Fishers-exact test. Correlations between
patient characteristics and prognosis were assessed using
univariate and multivariate logistic regression models.
All tests were two-sided and a P-value below 0.05 was
regarded as significant. SPSS 17.0 was used for all
analyses.
Results
A total of 302 patients received allogeneic HSCT during
the study period. The underline diseases are shown in
Table 1. The duration of underline diseases before trans-
plant ranged from 1 month to 37 months (median,
9 months). The demographics and transplant-related
data are shown in Table 2.
Of these patients, 29 cases made 31 total admissions
to PICU during the study period. Twenty-one (72.41 %)
died, 8 patients (27.59 %) were discharged from PICU.
The 30-day survival rate was 27.59 % (8/29). 6-month
survival rate was 24.14 % (7/29).
The most common indication for PICU admission was
respiratory failure (18 cases, 62.07 %). Of these patients,
4 cases had cardiovascular failure and 2 had renal failure
simultaneously. Four (13.79 %) patients presented with
neurological symptoms. Four (13.79 %) patients occurred
isolated renal failure. One presented with cardiac arrest.
The most common cause of respiratory failure was
severe pneumonia (72 %). The most common cause of
neurological pathology was central nervous system infec-
tion. Twenty patients (68.97 %) required mechanical
ventilation. Of those requiring mechanical ventilation,
17 died and 3 were extubated successfully. Thirteen pa-
tients received vasoactive agents. Four patients required
renal replacement therapy, and 3 of them died.
The comparisons of continuous and categorical clinical
variables between survivors and non-survivors are shown
in Tables 3 and 4. In their initial lab work, the patients
who died had a higher level of lactic acid (4.02 vs.
1.19 mmol/L, P = 0.008) and blood uria nitrogen (11.56 vs.
7.13 mmol/L, P = 0.045); lower pediatric critical illness
score (77 vs. 88, p = 0.004), more organs damaged (2.05
vs. 1.38, P = 0.01); more supportive therapies (1.52 vs.
0.63, P = 0.02), higher incidence of ventilator use (P =
0.04) and vasoactive agents use (P = 0.04). Univariate
analysis (Table 5) identified pediatric critical illness
score (PCIS), use of mechanical ventilation, number of sup-
portive therapy as the significant predictors of prognosis.


















Pure red cell aplasia 2
Fanconi anemia 1
Pyruvate kinase deficiency 1
ALL:acute lymphoblastic leukemia; AML: Acute myeloid leukemia; MDS:
myelodysplastic syndromes; CML: chronic myelogenous leukemia; JMML: juvenile
myelomonocytic leukemia; HPS: hemophagocytic syndrome; NHL: Non-Hodgkin's
Lymphoma; AA: aplastic anemia; PID: primary immunodeficiency diseases; SCID:
severe combined immunodeficiency disease; MPS: mucopolysaccharidosis;
NPD: Niemaoh-Pickdisease
An et al. BMC Pediatrics  (2016) 16:138 Page 2 of 5
Multivariate analysis by regression (Table 6) showed that
PCIS was an independent prognostic factor (P = 0.035).
Discussion
It is necessary to introduce the current situation of Chinese
pediatric HSCT. The pediatric transplantation centers
mainly concentrate in Beijing, Shanghai, and Guangzhou in
china. Most of the patients were treated by specialized
pediatric transplant physicians. A small percentage of pa-
tients received HSCT in adult department of Hematology/
Oncology. The precise number of pediatric HSCT per year
is not clear, however, in the first six month of 2015, the
transplantations included by the Chinese HSCT group in-
crease to 5000 cases, there are 800 under 20 years old, so
we speculate that pediatric transplantations possibly reach
500 cases. As for our center, from 2001–2005, a total of 31
cases underwent HSCT, from 2006–2010, 140 patients
underwent HSCT, from 2011–2014, 321 cases underwent
HSCT. With the increase of patients who have received
HSCT, there has been an increasing necessity for adequate
P ICU service to manage various transplant related compli-
cations. The supportive treatments provided include: lam-
inar flow, continuous renal replacement therapy, peritoneal
dialysis, noninvasive mechanical ventilation, invasive mech-
anical ventilation, and central venous pressure monitoring.
In this study we analyzed the outcome and prognostic
factors of these special patients in our center. The most
common indication for PICU admission was respiratory
failure; the most common cause of respiratory failure was
pneumonia, followed by diffuse alveolar hemorrhage. Pre-
vious studies also demonstrated that respiratory failure
was the main indication for admission [13, 14]. Similar
studies showed the most common cause of respiratory
failure was pneumonia (41 %, 43 %), followed by diffuse
alveolar hemorrhage (37 %, 29 %) [15, 16]. Fungal and
viral infections were common in these patients [16, 17].
Recent studies have suggested that the effective use of
non-invasive ventilation as early as possible can reduce
mortality [18, 19].
The other main reasons for admission to PICU were
neurological abnormalities and renal failure. The most
Table 2 Demographics and transplant-related data of patients
who were admitted to PICU (n = 29)
Variable Number




























Median time of duration pre-transplant (month) 9
Range 1-37
Median time of duration after completed transplantation (day) 74
Range 2-540
Table 3 Comparison of continuous clinical variables between survivors and non-survivors
Survivor Non-survivor Z P
Types of supportive therapies 0.63 1.52 −2.268 0.02
Duration after completed transplantation (day) 84 125.33 −0.098 0.094
PCIS 88 77 −2.792 0.004
Duration of MV (day) 4.88 4.67 −1.227 0.23
Length of PICU (day) 9.5 6.33 −1.720 0.09
Hospitalization time (day) 44.5 28.95 −1.294 0.20
Time course of disease before transplant (months) 16.25 9.76 −1.47 0.15
Number of organs involved 1.38 2.05 −2.450 0.01
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common cause of neurological abnormalities was central
nervous system infection. For children who had renal fail-
ure, the mortality rate was as high as 75 %. Previously de-
scribed common causes of renal failure in this patient
population were fluid overload due to hyper hydration,
intravenous antibiotics, and renal toxicity induced by con-
ditioning regimen [20]. Aggressive use of diuretics and
early initiation of renal replacement therapy can prevent
further deterioration of fluid overload, and improve the
prognosis of these children [21].
The proportion of patients requiring mechanical venti-
lation and/or vasoactive agents was significantly higher
in non-survivor group. Our analysis showed that gender,
underlying disease, conditioning regimen, donor type,
and presence of graft-versus-host disease had no signifi-
cant difference between the two groups.
Previous studies have reported prognostic risk factors
including: pulmonary infection, respiratory failure, multiple
organ failure (especially pulmonary failure and neurological
deterioration), mechanical ventilation, and vasoactive agent
support [6, 12, 15, 22]. Our study showed that mechan-
ical ventilation (P = 0.03), pediatric critical illness score
(P = 0.02), the number of supportive therapies (P = 0.04)
were risk factors for death. Although not significant at
the P = 0.05 level, it is also notable that the use of vaso-
active agents may also be predictive (P = 0.053). Multi-
variate analysis by regression showed that PCIS was the
only independent prognostic factor (P = 0.035).
PCIS is a widely used scoring system in China. The
emergency group of Chinese pediatric society, Chinese
medical association drew up it in 1995. The evaluated
objects, in addition to neonate, can be divided into two
groups according to age (≥1 year old or < 1 year old).
Ten physiological indexes are enrolled: heart rate, sys-
tolic blood pressure, spontaneous breath rate, oxygen
partial pressure under breathing room air, PH value of
arterial blood gas, serum sodium, potassium, creatinine
or urea nitrogen, hemoglobin, gastrointestinal system
condition (stress ulcer hemorrhage and intestinal paraly-
sis, only stress ulcer hemorrhage or other). The scoring
criteria is in accordance with the prescribed scope or
situation for each item, and then calculate the sum, if
there are more than one result of some indexes in the
same day, choose the most abnormal one. Total score is
100, if the patients’ score >80, were divided into non-
critical group, between 71 ~ 80, were critical group, 70
or less were extremely critical group. The pediatric
emergency group had organized two large-scale clinical
test of this scoring system; the results verified its useful-
ness in assessment of the severity of disease. Some
researchers evaluated the relationship between the
Pediatric risk of mortality score (PRISM) and PCIS, the
results showed that these two scoring system has good
correlation. So we think that PCIS is an objective, con-
venient test adapts to a rapid assessment of pediatric
Table 4 Comparison of clinical categorical variables between survivors and non-survivors
Survivor Non-survivor Chi-square value P
Gender (male/female) 15/6 5/3 0.216 0.68
Underlying disease: malignant/nonmalignant 3/5 12/9 0.895 0.43
Preconditioning: myeloablative/nonmyeloablative 4/4 14/5 2.032 0.34
Donor (related/unrelated) 1/7 10/11 3.035 0.11
aGVHD (Y/N) 3/5 9/12 0.069 1.0
MV (Y/N) 3/5 17/4 5.11 0.04
Renal replacement (Y/N) 1/7 3/18 0.016 1.0
Vasoactive agent (Y/N) 1/7 12/9 4.668 0.04
Y: yes; N: no




Underlying disease (malignant/nonmalignant) 0.35
Gender (male/female) 0.64
Mechanical ventilation 0.03







Types of supportive therapies 0.04
Table 6 Multivariate analysis of prognostic factors
Variable P
Mechanical Ventilation 0.06
Pediatric critical illness score 0.04
Vasoactive agent 0.05
Types of supportive therapy 0.05
An et al. BMC Pediatrics  (2016) 16:138 Page 4 of 5
critical ill patients. In this study when the PCIS was less
than 90, for every 10 points the score was below 90 the
odds ratio of death increased 4.2 times (OR = 4.24, 95 %
CI 1.30-13.79).
Conclusions
Pediatric allogeneic hematopoietic stem cell transplant-
ation recipients who requiring PICU treatment had high
mortality. The PCIS was an independent prognostic
factor for these patients.
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